Perrigo is expecting to begin product shipments to retailers during the first quarter of 2009.
The product will be marketed under store brand labels and is comparable to Wyeth Consumer Healthcare’s Advil PM tablets, 200/38mg, indicated as a pain reliever/night-time sleep-aid.
Joseph Papa, chairman and CEO of Perrigo, said: “We are obviously delighted by this latest approval, which is another example of Perrigo’s continuing investments to make quality healthcare more affordable to American consumers. Investments like this one help save over-the-counter healthcare consumers approximately $1 billion annually when compared to the higher priced national brands.”